The team

Cerapedics is a passionate, customer-focused, research-based team

The Cerapedics team is dedicated to enhancing the science of bone repair by staying at the leading edge of osteobiologic science and product development.

To find out more about the Cerapedics Board and Leadership Team, please see below.

The Board

Anthony Koblish

Antony Koblish

Anthony Koblish is a medical device entrepreneur with 25 years of experience who has served on the Cerapedics board of directors since 2013. He is currently co-founder, president and CEO of TELA Bio, a biosurgical reconstruction company. Prior to founding TELA Bio, Mr. Koblish was president and CEO of Orthovita, a publicly traded orthobiologics and biosurgery medical device company, where he helped grow the company’s valuation from $30 million to a $316 million sale to Stryker Corporation.

Glen Kashuba

Glen Kashuba

Glen Kashuba has over 30 years of executive management experience leading medical device companies. Prior to becoming CEO in 2013, Glen served as the Worldwide President of Spine & Bone Healing Technologies, Inc., a Biomet company, and concurrently served as Senior Vice President on Biomet’s Worldwide Operating Board, encompassing their Orthopedics, Spine, Trauma, Biologics, and Sports Medicine businesses. Previously, he has held a number of Divisional president roles at Johnson & Johnson where he served as Worldwide President for Cordis Endovascular and Neurovascular and as Worldwide President for Codman Neuro Sciences and U.S. President of DePuy Spine. Mr. Kashuba earned his B.S in Industrial Engineering from Rutgers University. He completed additional course work in corporate finance including a corporate valuation program at the Harvard Business School, and specialized study programs such as Bio-engineers in Surgery at Clemson University and Bio-mechanics Skeletal System at the New Jersey Institute Technology.

Kenneth Abramowitz

Kenneth Abramowitz

Kenneth Abramowitz is a co-founder and Managing General Partner of NGN Capital. He joined NGN Capital from The Carlyle Group in New York where he was Managing Director from 2001 to 2003, focused on U.S. buyout opportunities in the healthcare industry. Beginning July 2003, he transitioned to Senior Advisor at Carlyle in order to devote the time necessary to create a dedicated healthcare fund on behalf of Carlyle. Prior to joining Carlyle, Mr. Abramowitz worked as an Analyst at Sanford C. Bernstein & Co. where he covered the medical-supply, hospital-management and HMO industries for 23 years, after which he was an EGS Securities Healthcare Fund Manager. He was voted top hospital supply and/or service analyst on the Institutional Investor Magazine “All-America Research Team” during 15 out of 20 years between 1980-2000 and made “The Team” for both healthcare services and medical supplies for 9 years since 1987.

Douglas Kohrs

Douglas Kohrs

Douglas Kohrs has 35 years of experience in the medical device industry as a founder, board member, and executive of many innovative companies and non-profit organizations. He is currently managing director of Responsive Arthroscopy, a company focused on value-based healthcare solutions for sports medicine. Prior to Responsive Arthroscopy, Mr. Kohrs founded Responsive Orthopedics, which was acquired by Medtronic in 2016. He also has served as president and CEO of both organizations. He currently serves on the board of directors of six entities and is the president of the Foundation for Essential Needs, a non-profit focused on eradicating hunger.

Valeska Schroeder

Valeska Schroeder

Valeska has been a Managing Director of KCK’s Medical Technologies Investment Group since 2016. KCK is a single-family fund investing in a range of industries in private equity, growth capital, and venture capital, including a focus in medical technology. Valeska is a board member for KCK portfolio companies, including Cerapedics, Aerin Medical and BioInspire and a board observer for Intuity Medical and Reflexion Medical. Before joining KCK, Valeska held roles in product development, program management, and marketing in medical device companies, including VitalConnect, Acclarent, and NDC. Valeska obtained a BS, MS, and PhD from University of California at Berkeley in Materials Science and Engineering.

Greg Garfield

Greg Garfield

Greg Garfield currently serves as Head of Medical Technology Investments for the KCK Group. Previously, Greg was the General Manager of Laryngology and Emerging Therapies for J&J’s Acclarent subsidiary, which J&J purchased for $800M. Prior to this role, Greg served as Acclarent’s Chief Operating Officer focusing on developing and commercializing products for use by ENT physicians to improve and enhance patients’ lives. Greg has many years of experience in the medical technology industry in a variety of roles.

Andrew Tofe

Andrew Tofe, PHD

Andrew Tofe, PhD has over forty years of experience in developing and commercializing diagnostic and therapeutic products for bone disease and bone repair. This research and work in bone includes over 50 publications and patents. Dr. Tofe founded and served as President and Chief Executive Officer of CeraMed Dental, where he developed and brought to market three different types of bone substitutes, OsteoGraf®/N in 1990, OsteoGraf®/LD in 1994, PepGen P-15™ in 1999, and PepGen P-15 Flow in 2001. Dr. Tofe served as President and Chief Executive Officer from the transition of CeraMed Dental into Cerapedics, Inc until 2006.

Tyrell Rivers

Tyrell Rivers

Tyrell J. Rivers, Ph.D., has served as a member of the board of directors of Cerapedics since June 2018. Dr. Rivers is also an Executive Director within AstraZeneca’s Corporate Development group, having responsibility for equity investments, mergers and acquisitions, and divestments. Prior to this role, Dr. Rivers was at MedImmune Ventures where he specialized in biotechnology investing, and at Merck & Co., Inc. where he led the technical support for multiple commercial vaccine franchises and subsequently directed global business initiatives for accessing key technologies for research and development. Dr. Rivers earned his BS in Chemical Engineering from the Massachusetts Institute of Technology, a PhD in Chemical Engineering from University of Texas at Austin, and his MBA from the New York University Stern School of Business. Dr. Rivers serves on the board of directors for ADC Therapeutics SA, Armaron Bio Ltd, Corvidia Therapeutics and Viela Bio, Inc. and previously G1 Therapeutics, Inc. (GTHX) and PhaseBio Pharmaceuticals, Inc. (PHAS). He also serves as a board observer for several private companies.

Nael Kassar

Leadership

Glen Kashuba

Glen Kashuba

CEO

Glen Kashuba has over 30 years of executive management experience leading medical device companies. Prior to becoming CEO in 2013, Glen served as the Worldwide President of Spine & Bone Healing Technologies, Inc., a Biomet company, and concurrently served as Senior Vice President on Biomet’s Worldwide Operating Board, encompassing their Orthopedics, Spine, Trauma, Biologics, and Sports Medicine businesses. Previously, he has held a number of Divisional president roles at Johnson & Johnson where he served as Worldwide President for Cordis Endovascular and Neurovascular and as Worldwide President for Codman Neuro Sciences and U.S. President of DePuy Spine. Mr. Kashuba earned his B.S in Industrial Engineering from Rutgers University. He completed additional course work in corporate finance including a corporate valuation program at the Harvard Business School, and specialized study programs such as Bio-engineers in Surgery at Clemson University and Bio-mechanics Skeletal System at the New Jersey Institute Technology.

Jeffrey G. Marx, Ph.D.

Jeffrey G. Marx, Ph.D.

President & COO

Jeffrey Marx serves as President & Chief Operating Officer, overseeing regulatory, quality, manufacturing, and R&D efforts for the company. With some two decades of experience in executive management with medical device companies, he brings considerable expertise in research & development, commercialization, sales management, business development and strategic planning. His experience includes over 13 years with Orthovita, where he was VP Corporate Development. When Orthovita was acquired by Stryker Orthobiologics, Jeff led the team that integrated the two companies; he continued as VP Corporate Development at Stryker. He has earned a Ph.D. in Ceramic Engineering from Missouri University of Science and Technology, Rolla MO.

Drew Trivisonno

Drew Trivisonno

CFO

Drew Trivisonno brings two decades of financial operations management, and 10 years of experience in medical device mergers & acquisitions, along with debt & equity financing into his role as Cerapedics’ CFO. Previously, as VP with the venture capital firm Viscogliosi Bros., LLC, Drew helped to manage financing and acquisition projects with such companies as Knee Creations, Zimmer Corporation, Stryker, New Health Capital, PDL Biopharma, Small Bone Innovations, and many more. He earned his B.Sc. in Accounting at Babson College, Babson Park MA

Andrew W. Barnes

Andrew W. Barnes

VP of U.S. Sales

Andrew Barnes is an experienced leader within medical device sales, having held various leadership positions with leading companies in biologics, spine, orthopedic and maxillofacial medicine. Beginning his career with Synthes Trauma, Spine & Maxillofacial, Andy worked with such leading companies as Globus Medical, Stryker Orthobiologics/Orthovita, Medtronic and MacroPore Biosurgery before joining Cerapedics as Vice President of U.S. Sales.

Edward Sawyer

Edward Sawyer

General Manager

Edward Sawyer, General Manager, experienced Lifesciences operations and finance executive, MBA, CPA with experience across Lifescience disciplines. He is skilled at empowering people, merging processes and strategy, along with maximizing top and bottom line results. He has held budget responsibility of up to $800M and managed complex multifunctional personnel and teams. Track record of delivering solutions to complex problems and maximizing results of rapidly growing organizations.

 Jerome Connor, Ph.D.

Jerome Connor, Ph.D.

VP of Research and Development

Jerome Connor brings more than three decades of experience – both academic and corporate – in research and product development and specializes in the areas of soft tissue, hard tissue, and cell-based biology to his position as VP of Research and Development at Cerapedics. His previous positions include Assistant Professor at the University of Texas M.D. Anderson Cancer Center, and more than 20 years as Senior Director of Research and Development at LifeCell Corporation. Jerome earned his Ph.D. in Biochemistry at the University of Tennessee and received post-doctoral training at the M.D. Anderson Cancer Center of the University of Texas.

Roger N. White

Roger N. White

VP of Clinical and Regulatory Affairs

Roger White has amassed extensive regulatory, clinical and product development experience in his 35 years in the medical device industry. Before joining Cerapedics as VP of Clinical and Regulatory Affairs, his prior positions include founder and president of Phiama, Inc.; COO of Spine Wave, Inc., VP & Group Director of Quality Systems and Regulatory Affairs for Medtronic Surgical Navigation among others. Roger received B.S. and M.S. degrees in Biomedical Engineering from Louisiana Tech University. He has obtained more than 60 510(k) clearances, for devices in orthopedics and spine, image-guided surgery, microwave ablation and many more

Andy Woods

Andy Woods

Senior Director of OUS Commercial Development

Andy Woods has worked eight years in commercial development with Cerapedics. He acquired his expertise in the orthopaedic industry in senior level sales and marketing roles in reconstruction, trauma, spine and biologics. Prior to joining Cerapedics, he held leadership roles in Howmedica, Biomet, Orthovita and Orthogem. Over his 25-year career in the field, he has established commercial and marketing structures in both established firms and startups. Based in the UK, Andy works in the international arena, with subsidiary companies and distributor networks in all regions of the globe.

Scott Johnson

Scott Johnson, Ph.D

Senior Director of Clinical Education and Marketing

Bringing more than 15 years of experience to his role, Scott Johnson is responsible for strategic planning and tactical implementation of programs in professional education and clinical marketing. Scott’s perspective spans the technical and commercial aspects of orthopaedics, with roles in research and development, product innovation and clinical and business development. He holds B.Sc. and Ph.D. degrees with concentrations in musculoskeletal biology and biomechanics. Scott is based in the UK.

Patrick O'Connor

Patrick O'Connor

Vice President of Clinical and Market Development

Patrick O'Connor serves as Vice President of Clinical and Market Development supporting the coordination and execution of the ASPIRE IDE trial with an emphasis on facilitating patient enrollment and site relationship management. Most recently Mr. O’Connor served as Director of Market Development for Spinal Kinetics, an Orthofix Company, where he led patient education efforts and worked with surgeons to support clinical trial enrollment and market development. He has more than 15 years of experience in the medical instrument and surgery fields with roles including Director of Marketing New Technology for VertiFlex, Inc., and U.S. Group Product Manager of New Technology for Zimmer Spine. He holds a Master of Business Administration (MBA) from the University of Notre Dame.